About FDA

Division of Oncology Products 2 (DOP2)

The Division of Oncology Products 2 (DOP2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas: gastrointestinal, lung, and head and neck cancers; neuro-oncology, rare cancers, pediatric solid tumors, and melanoma and sarcoma.

Management Team
Director: Patricia Keegan, MD
Deputy Director: Joseph Gootenberg, MD
Associate Deputy Director: Steven Lemery, MD, MHS
Deputy Director for Safety: Jeff Summers, MD
Safety Regulatory Project Manager: Karen Hennessy, RN, MS, CPNP
Associate Director of Labeling (Acting): Stacy Shord, PharmD
Chief Project Management Staff: Melanie Pierce
Chief Project Management Staff: Monica Hughes, MS
Administrative Support Assistant: Charles Lewis

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Oncology Products 2 (DOP2)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Phone: (301) 796-2320
Fax: (301) 796-9849

Page Last Updated: 01/30/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English